Literature DB >> 10816446

Priming with Chlamydia trachomatis major outer membrane protein (MOMP) DNA followed by MOMP ISCOM boosting enhances protection and is associated with increased immunoglobulin A and Th1 cellular immune responses.

Z Dong-Ji1, X Yang, C Shen, H Lu, A Murdin, R C Brunham.   

Abstract

We previously reported that DNA vaccination was able to elicit cellular immune responses and partial protection against Chlamydia trachomatis infection. However, DNA immunization alone did not generate immune responses or protection as great as that induced by using live organisms. In this study, we evaluated the immunologic effects of a combinational vaccination approach using C. trachomatis mouse pneumonitis (MoPn) major outer membrane protein (MOMP) DNA priming followed by boosting with immune-stimulating complexes (ISCOM) of MOMP protein (MOMP ISCOM) for protection of BALB/c mice against MoPn lung infection. Substantially better protection to challenge infection was observed in mice given combinational vaccination compared with mice given MOMP ISCOM immunization alone, and the protection approximated that induced by live organisms. Enhanced protection was correlated with stronger delayed-type hypersensitivity, higher levels of gamma interferon production, and increased immunoglobulin A antibody responses in lung homogenates. The results indicate that DNA priming followed by ISCOM protein boosting may be useful in designing a fully protective chlamydial vaccine.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10816446      PMCID: PMC97534          DOI: 10.1128/IAI.68.6.3074-3078.2000

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  24 in total

1.  Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination.

Authors:  N L Letvin; D C Montefiori; Y Yasutomi; H C Perry; M E Davies; C Lekutis; M Alroy; D C Freed; C I Lord; L K Handt; M A Liu; J W Shiver
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-19       Impact factor: 11.205

2.  Induction of tryptophan catabolism is the mechanism for gamma-interferon-mediated inhibition of intracellular Chlamydia psittaci replication in T24 cells.

Authors:  G I Byrne; L K Lehmann; G J Landry
Journal:  Infect Immun       Date:  1986-08       Impact factor: 3.441

Review 3.  Chlamydial infections (third of three parts).

Authors:  J Schachter
Journal:  N Engl J Med       Date:  1978-03-09       Impact factor: 91.245

4.  Immunity to Chlamydia trachomatis mouse pneumonitis induced by vaccination with live organisms correlates with early granulocyte-macrophage colony-stimulating factor and interleukin-12 production and with dendritic cell-like maturation.

Authors:  D Zhang; X Yang; H Lu; G Zhong; R C Brunham
Journal:  Infect Immun       Date:  1999-04       Impact factor: 3.441

5.  Epidemiology of ocular chlamydial infection in a trachoma-hyperendemic area.

Authors:  S K West; P Rapoza; B Muñoz; S Katala; H R Taylor
Journal:  J Infect Dis       Date:  1991-04       Impact factor: 5.226

6.  Characterization of antibody responses to a Plasmodium falciparum blood-stage antigen induced by a DNA prime/protein boost immunization protocol.

Authors:  D Haddad; S Liljeqvist; S Ståhl; M Hansson; P Perlmann; N Ahlborg; K Berzins
Journal:  Scand J Immunol       Date:  1999-05       Impact factor: 3.487

7.  Protection of turkeys against Chlamydia psittaci challenge by gene gun-based DNA immunizations.

Authors:  D Vanrompay; E Cox; F Vandenbussche; G Volckaert; B Goddeeris
Journal:  Vaccine       Date:  1999-06-04       Impact factor: 3.641

8.  Genetically determined differences in IL-10 and IFN-gamma responses correlate with clearance of Chlamydia trachomatis mouse pneumonitis infection.

Authors:  X Yang; K T HayGlass; R C Brunham
Journal:  J Immunol       Date:  1996-06-01       Impact factor: 5.422

9.  Gene knockout mice establish a primary protective role for major histocompatibility complex class II-restricted responses in Chlamydia trachomatis genital tract infection.

Authors:  R P Morrison; K Feilzer; D B Tumas
Journal:  Infect Immun       Date:  1995-12       Impact factor: 3.441

10.  Role for CD8+ T cells in antichlamydial immunity defined by Chlamydia-specific T-lymphocyte clones.

Authors:  J U Igietseme; D M Magee; D M Williams; R G Rank
Journal:  Infect Immun       Date:  1994-11       Impact factor: 3.441

View more
  28 in total

Review 1.  Chlamydial infection in sheep: immune control versus fetal pathology.

Authors:  G Entrican; D Buxton; D Longbottom
Journal:  J R Soc Med       Date:  2001-06       Impact factor: 5.344

Review 2.  Immunity to murine chlamydial genital infection.

Authors:  Richard P Morrison; Harlan D Caldwell
Journal:  Infect Immun       Date:  2002-06       Impact factor: 3.441

Review 3.  Mucosal immunity: overcoming the barrier for induction of proximal responses.

Authors:  Brent S McKenzie; Jamie L Brady; Andrew M Lew
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

4.  Intranasal vaccination with a secreted chlamydial protein enhances resolution of genital Chlamydia muridarum infection, protects against oviduct pathology, and is highly dependent upon endogenous gamma interferon production.

Authors:  Ashlesh K Murthy; James P Chambers; Patricia A Meier; Guangming Zhong; Bernard P Arulanandam
Journal:  Infect Immun       Date:  2006-11-21       Impact factor: 3.441

5.  Vaccination with the Chlamydia trachomatis major outer membrane protein can elicit an immune response as protective as that resulting from inoculation with live bacteria.

Authors:  Sukumar Pal; Ellena M Peterson; Luis M de la Maza
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

6.  Immunogenicity of a vaccine formulated with the Chlamydia trachomatis serovar F, native major outer membrane protein in a nonhuman primate model.

Authors:  Chunmei Cheng; Sukumar Pal; Ilham Bettahi; Kristie L Oxford; Peter A Barry; Luis M de la Maza
Journal:  Vaccine       Date:  2011-03-04       Impact factor: 3.641

7.  Increased immunoaccessibility of MOMP epitopes in a vaccine formulated with amphipols may account for the very robust protection elicited against a vaginal challenge with Chlamydia muridarum.

Authors:  Delia F Tifrea; Sukumar Pal; Jean-Luc Popot; Melanie J Cocco; Luis M de la Maza
Journal:  J Immunol       Date:  2014-04-28       Impact factor: 5.422

8.  Immunization with the attenuated plasmidless Chlamydia trachomatis L2(25667R) strain provides partial protection in a murine model of female genitourinary tract infection.

Authors:  Norma Olivares-Zavaleta; William Whitmire; Donald Gardner; Harlan D Caldwell
Journal:  Vaccine       Date:  2009-12-08       Impact factor: 3.641

9.  Protection against an intranasal challenge by vaccines formulated with native and recombinant preparations of the Chlamydia trachomatis major outer membrane protein.

Authors:  Guifeng Sun; Sukumar Pal; Joseph Weiland; Ellena M Peterson; Luis M de la Maza
Journal:  Vaccine       Date:  2009-05-27       Impact factor: 3.641

10.  Chlamydia trachomatis native major outer membrane protein induces partial protection in nonhuman primates: implication for a trachoma transmission-blocking vaccine.

Authors:  Laszlo Kari; William M Whitmire; Deborah D Crane; Nathalie Reveneau; John H Carlson; Morgan M Goheen; Ellena M Peterson; Sukumar Pal; Luis M de la Maza; Harlan D Caldwell
Journal:  J Immunol       Date:  2009-06-15       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.